ONGA
NBIX icon

O'Neil Global Advisors’s Neurocrine Biosciences NBIX Stock Holding History

O'Neil Global Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,810
Closed -$250K – 61
2024
Q1 		$250K Buy
1,810
+275
+18% +$37.6K 0.31% 26
2023
Q4 		$202K Sell
1,535
-663
-30% -$76.3K 0.12% 51
2023
Q3 		$247K Buy
+2,198
New +$231K 0.22% 46
2023
Q1 		– Sell
-3,280
Closed -$392K – 81
2022
Q4 		$392K Sell
3,280
-601
-15% -$70.4K 1.81% 22
2022
Q3 		$412K Buy
+3,881
New +$394K 1.63% 27

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

O'Neil Global Advisors's NBIX Position: Q2 2024 in Review

O'Neil Global Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 1,810 shares — an estimated $250K sold.

O'Neil Global Advisors first reported a position in NBIX in Q3 2022 and held it in 5 quarters. The position peaked at $412K in Q3 2022. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • O'Neil Global Advisors reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • O'Neil Global Advisors sold 1,810 Neurocrine Biosciences shares in Q2 2024, an estimated $250K.
  • O'Neil Global Advisors first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 5 quarters.
  • O'Neil Global Advisors's Neurocrine Biosciences position peaked at $412K in Q3 2022.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on O'Neil Global Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.